Active substances
Naloxone + Oxycodone
- SFDA 3
- US FDA 1
- Health Canada 4
- NHS prices 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TARGINACT 10MG/5MG PR TABLET | 10,5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 110.25 | NCE · Prescription | Napp pharmaceuticals limited | Valid |
| TARGINACT 20MG/10MG PR TABLET | 20,10 mg,mg | Prolonged-release tablet · Oral use | 56 Blister | SAR 220.55 | NCE · Prescription | Napp pharmaceuticals limited | Valid |
| TARGINACT 40MG/20MG PR TABLET | 40,20 mg,mg | Prolonged-release tablet · Oral use | 56 Blister | SAR 421.95 | NCE · Prescription | Napp pharmaceuticals limited | Valid |
Indications — CHI Daman Drug Formulary
DIABETIC NEUROPATHY; ENDOMETRIOSIS; LOW BACK PAIN; NEUROPATHIC PAIN; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POST-HERPETIC NEURALGIA; POSTOPERATIVE PAIN; RENAL AND URETERIC STONES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TARGINIQ | 5MG;10MG; 10MG;20MG; 20MG;40MG | tablet, extended release · oral | PURDUE PHARMA LP | Discontinued | 23 Jul 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| TARGIN | 02339609 | 10 MG; 5 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| TARGIN | 02339617 | 20 MG; 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| TARGIN | 02339625 | 20 MG; 40 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
| TARGIN | 02387425 | 2.50 MG; 5.00 MG | TABLET (EXTENDED-RELEASE) · ORAL | PURDUE PHARMA |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Oxycodone 10mg / Naloxone 5mg modified-release tablets | £42.32 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 20mg / Naloxone 10mg modified-release tablets | £84.62 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 40mg / Naloxone 20mg modified-release tablets | £169.28 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxycodone 5mg / Naloxone 2.5mg modified-release tablets | £21.16 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.